Petruk G, Puthia P, Samsudin F, Petrlova J, Olm F, Mittendorfer M, Hyllén S, Edström D, Strömdahl A-C,
Diehl C, Ekström S,
Walse B, Kjellström S, Bond PJ, Lindstedt S & Schmidtchen A (2023).
Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs.
Nat Commun, 14, 6097. https://doi.org/10.1038/s41467-023-41702-y
PDB entries:8BWW - Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
Thrombin-derived C-terminal peptides (TCPs) are endogenous anti-infective immunomodulators interfering with CD14-mediated TLR-dependent immune responses. Using a combination of structure- and in silico-based design, nuclear magnetic resonance (NMR) spectroscopy, biophysics, mass spectrometry, cellular, and in vivo studies, the paper presents the structure, CD14 interactions, protease stability, transcriptome profiling, and therapeutic efficacy of sHVF18.
For a full list please visit our publications page.